TQB3454 in mutant IDH1 advanced cholangiocarcinoma (CCA): Results of a phase I dose escalation and expansion study cohort

被引：1
|
作者：
Yuan, J. [1 ]
Zheng, Y. [2 ]
Xu, L. [3 ]
Xie, F. [4 ]
Gu, S. [5 ]
Li, Q. [6 ]
Zhang, J. [7 ]
Ba, Y. [8 ]
Huaxin, D. [9 ]
Yang, A. [10 ]
Li, J. [10 ]
Zhou, J. [11 ]
Shen, L. [11 ]
机构：
[1] Peking Univ, Dept Gastrointestinal Oncol, Canc Hosp Inst, Beijing, Peoples R China
[2] Zhejiang Univ, Dept Oncol, Affiliated Hosp 1, Hangzhou, Peoples R China
[3] Sun Yat Sen Univ, Dept Liver Surg, Canc Ctr, Guangzhou, Peoples R China
[4] Chinese PLA Naval Mil Med Univ, Dept Surg, Affiliated Hosp 3, Shanghai, Peoples R China
[5] Hunan Canc Hosp, Intervent Div, Changsha, Peoples R China
[6] SCU Sichuan Univ, Dept Oncol, Huaxi Campus, Chengdu, Peoples R China
[7] Southern Med Univ, Dept Oncol, ZhuJiang Hosp, Zhujiang, Peoples R China
[8] Tianjin Med Univ, Dept Gastroenterol, Canc Inst & Hosp, Tianjin, Peoples R China
[9] Hunan Prov Peoples Hosp, Dept Oncol, Changsha, Peoples R China
[10] CTTQ Chia Tai Tianqing Pharmaceut Grp Co Ltd, Clin Med, Lianyungang, Peoples R China
[11] Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.292
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
286P
引用
收藏
页码：S120 / S120
页数：1
相关论文
共 50 条
  • [21] A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced IDH-mutant cholangiocarcinoma and other solid tumors
    Rodon, Jordi
    Goyal, Lipika
    Mercade, Teresa Macarulla
    Ikeda, Masafumi
    Kondo, Shunsuke
    Oh, Do-Youn
    Bai, Li-Yuan
    Ueno, Makoto
    Italiano, Antoine
    Papadopoulos, Kyriakos
    Spigel, David
    Kizilbash, Sani H.
    Cosman, Rasha
    Park, Joon Oh
    Chen, Li-Tzong
    Yokota, Tomoya
    Turk, Anita A.
    Liao, Chih-Yi
    Shroff, Rachna
    El-Khoueiry, Anthony
    Satoh, Taroh
    Hollebecque, Antoine
    Borad, Mitesh J.
    Azad, Nilofer
    Jaeckle, Kurt A.
    Loong, Herbert H.
    Adeva, Jorge
    Yong, Wei Peng
    Zhao, Junjie
    Liu, Hui
    Szpurka, Anna M.
    Gueorguieva, Ivelina
    Pradhan, Kamnesh R.
    Xu, Xiaojian
    Harding, James J.
    CANCER RESEARCH, 2023, 83 (08)
  • [22] Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study
    Bin Fan
    Ghassan K. Abou-Alfa
    Andrew X. Zhu
    Shuchi S. Pandya
    Hongxia Jia
    Feng Yin
    Camelia Gliser
    Zhaowei Hua
    Mohammad Hossain
    Hua Yang
    Cancer Chemotherapy and Pharmacology, 2024, 93 : 471 - 479
  • [23] Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study
    Fan, Bin
    Abou-Alfa, Ghassan K.
    Zhu, Andrew X.
    Pandya, Shuchi S.
    Jia, Hongxia
    Yin, Feng
    Gliser, Camelia
    Hua, Zhaowei
    Hossain, Mohammad
    Yang, Hua
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (05) : 471 - 479
  • [24] ENASIDENIB (AG-221) IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE-ESCALATION AND EXPANSION STUDY
    Stein, E. M.
    DiNardo, C. D.
    Pollyea, D. A.
    Fathi, A. T.
    Roboz, G. J.
    Altman, J. K.
    Stone, R. M.
    Flinn, I. W.
    Kantarjian, H. M.
    Collins, R.
    Patel, M. R.
    Stein, A.
    Sekeres, M. A.
    Swords, R. T.
    Medeiros, B. C.
    Knight, R. D.
    Agresta, S.
    de Botton, S.
    Tallman, M. S.
    HAEMATOLOGICA, 2017, 102 : 175 - 175
  • [25] Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation The Phase 3 Randomized Clinical ClarIDHy Trial
    Zhu, Andrew X.
    Macarulla, Teresa
    Javle, Milind M.
    Kelley, R. Kate
    Lubner, Sam J.
    Adeva, Jorge
    Cleary, James M.
    Catenacci, Daniel V. T.
    Borad, Mitesh J.
    Bridgewater, John A.
    Harris, William P.
    Murphy, Adrian G.
    Oh, Do-Youn
    Whisenant, Jonathan R.
    Lowery, Maeve A.
    Goyal, Lipika
    Shroff, Rachna T.
    El-Khoueiry, Anthony B.
    Chamberlain, Christina X.
    Aguado-Fraile, Elia
    Choe, Sung
    Wu, Bin
    Liu, Hua
    Gliser, Camelia
    Pandya, Shuchi S.
    Valle, Juan W.
    Abou-Alfa, Ghassan K.
    JAMA ONCOLOGY, 2021, 7 (11) : 1669 - 1677
  • [26] Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
    DiNardo, Courtney D.
    Foran, James M.
    Watts, Justin M.
    Stein, Eytan M.
    de Botton, Stephane
    Fathi, Amir T.
    Prince, Gabrielle T.
    Stein, Anthony S.
    Stone, Richard M.
    Patel, Prapti A.
    Roboz, Gail J.
    Arellano, Martha L.
    Erba, Harry P.
    Pigneux, Arnaud
    Stuart, Robert K.
    Thomas, Xavier
    Uy, Geoffrey L.
    Oluyadi, Abdulafeez
    Lemieux, Ian R.
    Liu, Hua
    Wu, Bin
    Winkler, Thomas
    Garcia-Manero, Guillermo
    Sallman, David A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S321 - S321
  • [27] Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study
    DiNardo, Courtney D.
    Watts, Justin M.
    Stein, Eytan M.
    De Botton, Stephane
    Fathi, Amir T.
    Prince, Gabrielle T.
    Stein, Anthony S.
    Foran, James M.
    Stone, Richard M.
    Patel, Prapti A.
    Tallman, Martin S.
    Choe, Sung
    Wang, Hongfang
    Zhang, Vickie
    Dai, David
    Fan, Bin
    Yen, Katharine E.
    Kapsalis, Stephanie M.
    Hickman, Denice
    Agresta, Samuel V.
    Liu, Hua
    Wu, Bin
    Attar, Eyal C.
    Kantarjian, Hagop M.
    BLOOD, 2018, 132
  • [28] A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1.
    Mellinghoff, Ingo K.
    Cloughesy, Timothy Francis
    Wen, Patrick Y.
    Taylor, Jennie Webster
    Maher, Elizabeth A.
    Arrillaga, Isabel
    Peters, Katherine B.
    Choi, Changho
    Ellingson, Benjamin M.
    Lin, Alexander P.
    Thakur, Sunitha B.
    Nicolay, Brandon
    Lu, Min
    Le, Kha
    Yin, Feng
    Tai, Feng
    Schoenfeld, Steven
    Steelman, Lori
    Pandya, Shuchi Sumant
    Clarke, Jennifer Leigh
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
    Sullivan, Ryan J.
    Infante, Jeffrey R.
    Janku, Filip
    Wong, Deborah Jean Lee
    Sosman, Jeffrey A.
    Keedy, Vicki
    Patel, Manish R.
    Shapiro, Geoffrey I.
    Mier, James W.
    Tolcher, Anthony W.
    Wang-Gillam, Andrea
    Sznol, Mario
    Flaherty, Keith
    Buchbinder, Elizabeth
    Carvajal, Richard D.
    Varghese, Anna M.
    Lacouture, Mario E.
    Ribas, Antoni
    Patel, Sapna P.
    DeCrescenzo, Gary A.
    Emery, Caroline M.
    Groover, Anna L.
    Saha, Saurabh
    Varterasian, Mary
    Welsch, Dean J.
    Hyman, David M.
    Li, Bob T.
    CANCER DISCOVERY, 2018, 8 (02) : 184 - 195
  • [30] Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
    Mellinghoff, Ingo K.
    Penas-Prado, Marta
    Peters, Katherine B.
    Burris, Howard A.
    Maher, Elizabeth A.
    Janku, Filip
    Cote, Gregory M.
    de la Fuente, Macarena, I
    Clarke, Jennifer L.
    Ellingson, Benjamin M.
    Chun, Saewon
    Young, Robert J.
    Liu, Hua
    Choe, Sung
    Lu, Min
    Le, Kha
    Hassan, Islam
    Steelman, Lori
    Pandya, Shuchi S.
    Cloughesy, Timothy F.
    Wen, Patrick Y.
    CLINICAL CANCER RESEARCH, 2021, 27 (16) : 4491 - 4499
12345